Food and Drug Administration, HHS.
Notice of meeting.
The Food and Drug Administration (FDA) is announcing a public meeting entitled “Preparation for ICH meetings in Washington, DC” to provide information and receive comments on the International Conference on Harmonization (ICH) as well as the upcoming meetings in Washington, DC. The topics to be discussed are the topics for discussion at the forthcoming ICH Steering Committee Meeting. The purpose of the meeting is to solicit public input prior to the next Steering Committee and Experts Working Groups meetings in Washington, DC, June 7-10, 2004, at which discussion of the topics underway and the future of ICH will continue.
Date and Time: The meeting will be held on May 17, 2004, from 1:30 to 4:30 p.m.
Location: The meeting will be held at 5600 Fishers Lane, 3d floor, Potomac Conference Room, Rockville, MD 20857. For security reasons, all attendees are asked to arrive no later than 1:30 p.m., as you will be escorted from the front entrance of 5600 Fishers Lane to the Potomac Conference Room.
Contact Person: Sema Hashemi, Office of the Commissioner, Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-827-3050, FAX: 301-480-0716, e-mail: Sema.Hashemi@fda.hhs.gov.
Registration and Requests for Oral Presentations: Send registration information (including name, title, firm name, address, telephone, and fax number), and written material and requests to make oral presentations, to the contact person by May 7, 2004.
Transcripts: Transcripts of the meeting may be requested in writing from the Freedom of Information Office (HFI-35), Food and Drug Administration, 5600 Fishers Lane, rm. 12A-16, Rockville, MD 20857, approximately 15 working days after the meeting at a cost of 10 cents per page.
If you need special accommodations due to a disability, please contact Sema Hashemi at least 7 days in advance.End Preamble Start Supplemental Information
The ICH was established in 1990 as a joint regulatory/industry project to improve, through harmonization, the efficiency of the process for developing and registering new medicinal products in Europe, Japan, and the United States without compromising the regulatory obligations of safety and effectiveness.
In recent years, many important initiatives have been undertaken by regulatory authorities and industry associations to promote international harmonization of regulatory requirements. FDA has participated in many meetings designed to enhance harmonization and is committed to seeking scientifically based harmonized technical procedures for pharmaceutical development. One of the goals of harmonization is to identify and then reduce differences in technical requirements for medical product development among regulatory agencies. ICH was organized to provide an opportunity for harmonization initiatives to be developed with input from both regulatory and industry representatives. ICH is concerned with harmonization among the following three regions: The European Union, Start Printed Page 22540Japan, and the United States. The six ICH sponsors are the European Commission, the European Federation of Pharmaceutical Industries Associations, the Japanese Ministry of Health, Labor and Welfare, the Japanese Pharmaceutical Manufacturers Association, the Centers for Drug Evaluation and Research and Biologics Evaluation and Research, FDA, and the Pharmaceutical Research and Manufacturers of America. The ICH Secretariat, which coordinates the preparation of documentation, is provided by the International Federation of Pharmaceutical Manufacturers Associations (IFPMA). The ICH Steering Committee includes representatives from each of the ICH sponsors and Health Canada, the European Free Trade Area and the World Health Organization. The ICH process has achieved significant harmonization of the technical requirements for the approval of pharmaceuticals for human use in the three ICH regions.
The current ICH process and structure can be found at the following Web site: http://www.ich.org. Interested persons may present data, information, or views orally or in writing, on issues pending at the public meeting. Oral presentations from the public will be scheduled between approximately 3:45 p.m. and 4:30 p.m. Time allotted for oral presentations may be limited to 10 minutes. Those desiring to make oral presentations should notify the contact person by May 7, 2004, and submit a brief statement of the general nature of the evidence or arguments they which to present, the names and addresses, phone number, fax, and e-mail of proposed participants, and an indication of the approximate time requested to make their presentation.
The agenda for the public meeting will be made available on May 3, 2004, via the Internet at http://www.fda.gov/cder/meeting/ICH_05172004.htm.Start Signature
Dated: April 19, 2004.
Assistant Commissioner for Policy.
[FR Doc. 04-9323 Filed 4-23-04; 8:45 am]
BILLING CODE 4160-01-S